Company Overview and News

Esmya Restriction In Europe Could Handcuff Allergan

2018-05-21 seekingalpha
AGN is seeking FDA approval for Esmya in the U.S. EMA findings could jeopardize FDA approval or hurt Esmya sales.

Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

2018-05-11 seekingalpha
Alpine is leveraging on its stellar therapeutic innovation platforms (TIP and vIgD) to deliver the next-generation immuno-oncology (I-O) therapeutics.

Aptose Announces Appointment of Caroline M. Loewy to Board of Directors

2018-04-25 globenewswire
SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Caroline M. Loewy to the Board of Directors effective immediately. Aptose’s Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development.

Startup Terns Secures Three NASH Assets From Eli Lilly

2018-04-04 biospace
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following.

Xconomy: Tobira Fails Main Goal in NASH Study, But Forges Ahead To Next Trial

2018-02-11 xconomy
[Updated, 9:40 a.m. ET, see below] Developing treatments for nonalcoholic steatohepatitis, a dangerous liver disease that’s fast becoming an epidemic, is one of the most competitive fields in biotech. Tobira Therapeutics is one of several companies in the mix, and although data released this morning cast doubt on the potential of its drug, the company plans to forge ahead nonetheless.

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan.

ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List

2018-02-06 seekingalpha
Readers are encouraged to make their voices heard in my recent blog post if they haven´t already.

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

2018-02-02 seekingalpha
I encourage readers to check out my recent blog post which goes into detail regarding changes to Seeking Alpha and consequently to ROTY.

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

2018-01-30 seekingalpha
So far feedback has been positive for new features added, namely the position explanation section and updated model account snapshot.

2 Small Biotechs With Substantial Upside Potential

2018-01-26 seekingalpha
The biotech sector is perking up this week on the back of two big acquisitions and improved sentiment on the space.

ROTY Edition 1 Volume 73: New Features And A Controversial Swap Out

2018-01-25 seekingalpha
We are swapping out a current holding for a recent addition to the Contenders List (please read full write-up and be aware of risks).

Can-Fite Partners with Hadassah Medical Center to Target Unmet Need for NASH Drugs

2018-01-08 accesswire
SANTA MONICA, CA / ACCESSWIRE / January 8, 2018 / Non-alcoholic steatohepatitis, or NASH as it is more frequently called, is an advanced form of non-alcoholic fatty liver disease (NAFLD) characterized by buildup of fat in the liver and related inflammation and damage not caused by alcohol use. In some biotech circles, NASH is understandably called the next great untapped market due to the fact that there is a dearth of treatments for the disease that affects up to 30 million Americans.

Conatus: Likely To Dash Ahead Of NASH Data

2017-12-13 seekingalpha
Conatus, with emricasan, seeks to halt the progression of liver disease in four separate phase 2 trials.

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

15h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

15h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 88883P101